Since the systemic delivery of AAV9 serotype transduces HO-causing FAPs in skeletal muscle [9], the AAV9-mediated correction of ACVR1R206H mutation using the Nme2-ABE/sgRNA might be a promising therapeutic strategy for a permanent cure for HO in FOP patients. Here, NME2 is linked to fibrodysplasia ossificans progressiva.